Finance

Beta
Lists
FARN:LON
Faron Pharmaceuticals Oy
GBX 46.00
0.00%
(0.00) 1D
Jun 3, 4:30:00 PM GMT+1  ·   GBX
All symbols
SymbolPriceChange% Change
Generating top insights for FARN...
Open
GBX 45.00
High
GBX 46.30
Low
GBX 45.00
Mkt. cap
91.69M
Avg. vol.
87.40K
Volume
7.84K
52-wk high
GBX 230.45
52-wk low
GBX 38.00
EPS
-GBX 0.19
Shares outstanding
31.03M
No. of employees
33
Open
GBX 45.00
High
GBX 46.30
Low
GBX 45.00
Mkt. cap
91.69M
Avg. vol.
87.40K
Volume
7.84K
52-wk high
GBX 230.45
52-wk low
GBX 38.00
EPS
-GBX 0.19
Shares outstanding
31.03M
No. of employees
33
News stories
From sources across the web
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland. The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy. Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS. In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy
CEOMarkku Jalkanen
Employees33
Founded2003
Headquarters-
SectorBiotechnology
Websitefaron.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
3.56M
3.56M
2.77M
2.77M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.40M
2.40M
1.41M
1.41M
Operating expense
5.95M
5.95M
4.18M
4.18M
Total operating expenses
5.95M
5.95M
4.18M
4.18M
Operating income
-5.95M
-5.95M
-4.18M
-4.18M
Other non operating income
-500.00
-500.00
-3.48M
-3.48M
EBT including unusual items
-9.71M
-9.71M
-3.92M
-3.92M
EBT excluding unusual items
-9.71M
-9.71M
-4.57M
-4.57M
Income tax expense
-
-
1.00K
1.00K
Effective tax rate
-
-
-0.03%
-0.03%
Other operating expenses
-
-
-
-
Net income
-9.71M
-9.71M
-3.92M
-3.92M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
301.00K
301.00K
3.42M
3.42M
Interest expense
-4.06M
-4.06M
-273.00K
-273.00K
Net interest expenses
-3.76M
-3.76M
3.15M
3.15M
Depreciation and amortization charges
-
-
-
-
EBITDA
-5.88M
-5.88M
-4.14M
-4.14M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer